deltatrials
Terminated NA INTERVENTIONAL 2-arm NCT03489109

2-5 Intermittent Caloric Restriction in HIV (2-5toWIN)

2-5 Intermittent Caloric Restriction for Weight Loss and Insulin Resistance in HIV-Infected Adults With Features of the Metabolic Syndrome

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Human Immunodeficiency Virus Metabolic Syndrome
Interventions Intermittent fasting Standard of Care
Updated 18 times since 2018 Last updated: Oct 19, 2022 Started: May 9, 2018 Primary completion: Dec 17, 2021 Completion: Dec 17, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow/Insufficient accrual

Other terminated trials from National Institute of Allergy and Infectious Diseases (NIAID)

See all terminations from National Institute of Allergy and Infectious Diseases (NIAID)

Other Human Immunodeficiency Virus trials with similar outcome

Browse all Human Immunodeficiency Virus trials

A NA clinical study on Human Immunodeficiency Virus and Metabolic Syndrome, this trial is terminated or withdrawn. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 18 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Feb 2019 · 4 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Mar 2020 · 11 months · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Nov 2020 · 6 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Dec 2021 · 10 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Nov 2022 · 10 months · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated NA

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated NA

  3. Nov 2022 — Jul 2024 [monthly]

    Terminated NA

    Phase: PHASE2 → NA

  4. Jan 2022 — Nov 2022 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  5. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

▶ Show 13 earlier versions

  1. Feb 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  2. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  3. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  4. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  5. May 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  6. Mar 2020 — May 2020 [monthly]

    Recruiting PHASE2

  7. Apr 2019 — Mar 2020 [monthly]

    Recruiting PHASE2

    Phase: PHASE1 → PHASE2

  8. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE1

  9. Oct 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  10. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  11. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  12. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  13. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations